FDA Clearance Tracker · P910007-S019
ABBOTT ARCHITECT TOTAL PSA
Last checked: Nov 20, 2026Latest source record: Mar 22, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Mar 22, 2011
Approved
Time to decision
239 days
Received Jul 26, 2010. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P910007-S019
- Device name
- ABBOTT ARCHITECT TOTAL PSA
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- Jul 26, 2010
- Decided
- Mar 22, 2011
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P910007
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR MANUFACTURING SITE LOCATED AT ABBOTT IRELAND DIAGSNOSTICS DIVISION IN SLIGO, IRELAND.
Source documents
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.